Epidemiology of malignant tumours of the gastrointestinal tract in the Czech Republic – state of the art and prediction

Czech version

Authors: L. Dušek; J. Mužík; T. Pavlík; O. Májek; J. Koptíková
Authors‘ workplace: Institut biostatistiky a analýz, Masarykova univerzita, Brno
Published in: Gastroent Hepatol 2012; 66(5): 331-339
Category: Gastrointestinal Oncology: Review Article

Overview

Malignant tumours of the gastrointestinal tract (GIT) represent, from the epidemiological point of view, a heterogeneous group that includes cancer diagnoses both frequent (colorectal or pancreatic carcinoma) and rare (GIST, liver, small intestine and anal cancer, neuroendocrine tumours of the GIT). GIT tumours significantly contribute to the total cancer burden of the Czech population, which is also documented by international comparisons (3^rd place in incidence and 8^th place in mortality in Europe). According to the Czech National Cancer Registry data, 14,479 new GIT tumours were diagnosed and 9,122 patients died in 2009. Incidence of all GIT tumours has increased by 5% since 1999, while mortality has fallen by 7% in the same period. The trends therefore show prolonged survival of Czech patients. Improved 5-year relative survival in the period 2005–2009 has been documented particularly for oesophagus and colorectal carcinoma (7–10%) in comparison to periods before 1999; a moderate improvement has also been recorded for stomach cancer (5.5%). On the other hand, relative survival has not shifted in the last ten years for malignant tumours of the liver, intrahepatic bile ducts, gallbladder and pancreas. Increasing incidence, together with stable or decreasing mortality, has resulted in the rising prevalence of GIT tumours, which reached 58,343 persons in 2009.

Key words:
malignant tumours – digestive tract – epidemiology

The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study.

The Editorial Board declares that the manuscript met the ICMJE „uniform requirements“ for biomedical papers.

Submitted:
14. 9. 2012

Accepted:
4. 10. 2012

Sources

1. Ferlay J, Shin HR, Bray F et al. GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [online]. Lyon, France: International Agency for Research on Cancer 2010, [cit. 5. 9. 2012]. Dostupné z: http://globocan.iarc.fr.

2. Dušek L, Žaloudík J, Indrák K. Informační zázemí pro využití onkologických populačních dat v ČR. Klin Onkol 2007; 20 (Suppl 1).

3. Český statistický úřad. Demografická příručka 2007, [cit. 4. 9. 2012]. Dostupné z: http://www.czso.cz/csu/2008edicniplan.nsf//publ/4032-08-2007.

4. www.uzis.cz/info.php?article=368&mnu_id=7300.

5. Dušek L, Mužík J, Kubásek M et al. Epidemiologie zhoubných nádorů v České republice [online]. Masarykova univerzita, 2005, [cit. 4. 9. 2012]. Dostupné z: www.svod.cz . Verze 7.0 [2007], ISSN 1802–8861.

6. Verdecchia A, Francisci S, Brenner H et al. Recent cancer survival in Europe: a 2000–2002 period analysis of EUROCARE-4 data. Lancet Oncol 2008; 8(9): 784–796.

7. Dušek L (ed.). Czech Cancer Care in Numbers 2008-2009. Praha: Grada Publishing 2009.

8. Pavlík T, Májek O, Mužík J et al. Estimating the number of colorectal cancer patients treated with anti-tumour therapy in 2015: the analysis of the Czech National Cancer Registry. BMC Public Health 2012; 12: 117.

9. Organisation for Economic Co-operation and Development. Health at a Glance 2009: OECD Indicators. Paris: OECD Publishing 2009.

10. Organisation for Economic Co-operation and Development. Health at a Glance: Europe 2010. Paris: OECD Publishing 2010.

11. Organisation for Economic Co-operation and Development: Health at a Glance 2011: OECD Indicators. Paris: OECD Publishing 2011.